Clinical trial
Safety and Pharmacology of Stanate
NCT00115544 · InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company, Industry · Completed
Key facts
| NCT number | NCT00115544 |
|---|---|
| Title | Safety and Pharmacology of Stanate |
| Official title | An Open-Label Study of the Safety and Clinical Pharmacology of Stanate® in Infants At-Risk for Exchange Transfusion |
| Lead sponsor | InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company, Industry |
| Collaborators | National Children's Hospital, Vietnam |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hyperbilirubinemia |
| Intervention type | Drug |
| Interventions | Stanate |
| Enrollment | 55 |
| Start date | Sep 1, 2005 |
| Primary completion | Jul 1, 2006 |
| Completion | Jul 1, 2006 |
| First posted | Jun 23, 2005 |
| Last update posted | Oct 15, 2019 |
| Countries | Vietnam |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: